Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
CIWA-Ar is a structured bedside withdrawal severity scale used to monitor alcohol withdrawal progression and guide protocolized treatment intensity in supervised care settings.
Formula: CIWA-Ar total = sum of 10 domain scores (range 0-67).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The CIWA-Ar requires clinician administration with both direct patient questioning and physical observation. Nine items are scored 0-7: nausea/vomiting (ask about nausea, observe vomiting), tremor (extend arms, observe for tremor), paroxysmal sweats (observe for diaphoresis), anxiety (assess subjective anxiety level), agitation (observe motor behavior), tactile disturbances (ask about itching, pins-and-needles sensations, burning), auditory disturbances (ask about sounds seeming too loud, strange sounds, hallucinations), visual disturbances (ask about visual changes, photophobia, visual hallucinations), and headache/fullness in head (ask about head pressure or headache). The orientation item is scored 0-4 based on ability to perform serial additions or state the date correctly.
After assessing all 10 items, sum the individual scores. The maximum possible total is 67 (nine items x 7 + orientation x 4). In clinical practice, the CIWA-Ar is typically reassessed every 1-8 hours depending on severity. Assessment frequency should increase as scores rise — patients with scores 10-19 should be assessed every 1-2 hours; those with scores 20+ should be assessed continuously with ICU-level monitoring. Document the time of each assessment, total score, and any administered medications.
Below 10 (mild withdrawal): pharmacotherapy not usually required; can often be managed with supportive care, IV fluids, and monitoring. 10-19 (moderate withdrawal): pharmacotherapy is required — typically benzodiazepines using a symptom-triggered protocol. Score 20 and above (severe withdrawal): high risk for seizures and delirium tremens — requires intensive monitoring, aggressive benzodiazepine treatment, and ICU-level care consideration. All patients receive thiamine 100-500mg IV or IM before any dextrose-containing fluids.
Hospitalists and Internal Medicine
The CIWA-Ar is the standard structured monitoring tool for alcohol withdrawal in medical and surgical inpatient units. Serial assessments guide symptom-triggered benzodiazepine dosing, reducing total benzodiazepine use by 69% compared to fixed-schedule dosing while maintaining equivalent safety.
Emergency Physicians
Patients presenting to the ED in early alcohol withdrawal require rapid CIWA-Ar assessment to determine severity and need for immediate pharmacotherapy. CIWA-Ar above 10 warrants ED treatment and consideration for hospital admission; above 20 requires ICU consultation.
Intensivists
Delirium tremens (DTs) carries 5-15% mortality without treatment and requires ICU-level care with high-dose benzodiazepines. CIWA-Ar guides escalation to ICU-level management and dosing adjustments in patients with severe withdrawal requiring continuous monitoring.
Addiction Medicine Specialists
Addiction medicine units use the CIWA-Ar as the cornerstone of symptom-triggered benzodiazepine protocols, replacing fixed-schedule dosing and enabling individualized, evidence-based management of alcohol withdrawal severity.
Nurses
Nursing staff administer the CIWA-Ar at regular intervals and administer benzodiazepines when scores exceed predetermined thresholds (typically 8-10). This nurse-driven, symptom-triggered protocol is supported by JAMA-level evidence and is standard in hospital alcohol withdrawal management.
Addiction Specialists
In patients with mild-moderate withdrawal histories, the CIWA-Ar can guide decisions about outpatient vs inpatient detoxification. Patients with CIWA-Ar scores below 10 and no history of withdrawal seizures or DTs can potentially be managed in supervised outpatient detoxification programs.
The landmark Saitz et al. (1994) JAMA study demonstrated that symptom-triggered benzodiazepine dosing guided by CIWA-Ar reduced total benzodiazepine use by 69% compared to fixed-schedule dosing (every 4-6 hours regardless of symptoms), with equivalent safety outcomes. Symptom-triggered protocols reduce over-sedation, respiratory depression, and prolonged hospital stays. CIWA-Ar-guided symptom-triggered dosing is now the evidence-based standard of care for alcohol withdrawal management.
The timeline of alcohol withdrawal complications is clinically important for risk assessment. Minor withdrawal (tremor, diaphoresis, anxiety) begins 6-24 hours after last drink. Alcohol withdrawal seizures peak at 12-48 hours. Delirium tremens (hallucinations, disorientation, autonomic instability) develops in 3-5% of withdrawing patients and typically begins 48-72 hours after last drink, with peak risk at 72-96 hours. Any patient presenting in moderate-severe withdrawal within the first 24 hours is at high risk for DTs as the withdrawal syndrome progresses.
Thiamine (vitamin B1) 100-500mg IV or IM must be administered before any dextrose-containing IV fluids in alcohol withdrawal patients. Glucose loading without thiamine in patients with borderline thiamine stores can precipitate Wernicke's encephalopathy — a potentially irreversible neurological emergency characterized by ophthalmoplegia, ataxia, and confusion. This is a high-stakes clinical error: the thiamine before dextrose rule should be memorized and followed without exception in all patients with alcohol use disorder.
Diazepam (Valium) is preferred over lorazepam for alcohol withdrawal seizure prophylaxis due to its long half-life (20-100 hours) and long-acting active metabolites, which provide smoother CNS suppression and more durable seizure protection. Lorazepam is preferred in patients with liver disease (less hepatic metabolism) or respiratory compromise. For ICU management of very high CIWA-Ar scores, phenobarbital or propofol may be used as benzodiazepine alternatives or adjuncts.
The orientation/sensorium item of the CIWA-Ar is scored 0-4 rather than 0-7. A score of 4 represents very severe disorientation — the patient cannot state their location or recognize familiar persons. This level of cognitive impairment in the context of alcohol withdrawal indicates encephalopathy and is a warning sign for impending DTs. Any patient with an orientation score of 3-4 should be assessed immediately for ICU transfer.
Alcohol withdrawal patients are commonly hypomagnesemic, hypokalemic, and hypophosphatemic due to poor nutrition and alcohol's effects on renal tubular function. Hypomagnesemia independently lowers the seizure threshold and must be corrected. Check and replete magnesium, potassium, and phosphate in all alcohol withdrawal patients. IV magnesium sulfate should be given empirically in patients with no contraindication. Nutritional supplementation with multivitamins including folate and thiamine is standard care.
Any patient with a history of prior alcohol withdrawal seizures or delirium tremens is at substantially elevated risk for recurrence and should be admitted for inpatient monitoring regardless of CIWA-Ar score at presentation. Prior DTs is one of the strongest predictors of severe withdrawal syndrome on subsequent alcohol cessation. Do not attempt outpatient alcohol detoxification in patients with prior DTs or withdrawal seizures.
The CIWA-Ar requires patient participation — the patient must be awake, responsive, and able to report symptoms. It cannot be validly administered to intubated, heavily sedated, or severely delirious patients who cannot communicate. In these situations, the CIWA-B (Buss-based scale for sedated patients) or clinical gestalt with vital sign monitoring is used. Attempting to use CIWA-Ar in non-communicative patients produces artificially low scores that will underestimate withdrawal severity.
CIWA-Ar published by Sullivan et al. (Br J Addict 1989) as a revision of the original CIWA (1981). Symptom-triggered benzodiazepine protocol vs fixed-schedule (Saitz et al., JAMA 1994): reduced benzodiazepine use by 69% with equivalent safety. DTs mortality without treatment approximately 5-15%; with treatment less than 1%. ASAM Clinical Practice Guideline for Alcohol Withdrawal Management (2020) recommends CIWA-Ar for monitoring. Wernicke-Korsakoff prevention: thiamine before dextrose (Campbell 1988 Lancet review). Diazepam preferred for withdrawal seizure prophylaxis due to long half-life.
Higher CIWA-Ar totals indicate more severe alcohol withdrawal signs and typically support more intensive supervised management and reassessment frequency.
Use in monitored withdrawal care pathways for patients at risk of alcohol withdrawal to trend severity and support protocolized treatment decisions.
The score depends on patient interaction and may be unreliable with severe confusion, communication barriers, or competing neurologic/medical causes of symptoms.
For related assessments, see AUDIT, CAGE and BAC Calculator.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Screen for hazardous and harmful alcohol use with the 10-question AUDIT. Scores range from 0 to 40 across four risk zones. For quick screening use [CAGE](/tools/cage).
OpenMental HealthQuick four-question alcohol screening using the CAGE questionnaire. A score of 2 or more suggests possible alcohol problems. For comprehensive screening, use [AUDIT](/tools/audit).
OpenClinicalEstimate blood alcohol concentration (BAC) from standard drinks, body weight, sex, and time since drinking started using a Widmark-style model. Screen for alcohol use disorder with [AUDIT](/tools/audit) or [CAGE Questionnaire](/tools/cage).
Open